FDA Approves Gemtuzumab Ozogamicin for CD33-Positive AML in Pediatric Patients
On June 16, 2020, the Food and Drug Administration extended the indication of gemtuzumab ozogamicin (MYLOTARGTM, Wyeth Pharmaceuticals LLC) for newly-diagnosed CD33-positive acute myeloid leukemia (AML) to include pediatric patients 1 month and older.
On June 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA®, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.
Categories
- Blog Posts (65)
- Guest Blogs (18)
- Member Blogs (24)
- Survivorship Matters Blog (9)
- CAC2 News (21)
- Collaborative Achievements (13)
- Community News (169)
- News Digest (129)
- Research Explained (10)
- Webinars (61)
Tags
#CancelChildhoodCancer (1)
Advocacy (47)
Annual Summit (7)
Awareness (20)
AYA (2)
Best Practices (12)
Biorepositories (2)
CAC2 News (7)
CAC2 Project Incubator (1)
CAC2 Projects (11)
Call to Action (24)
Cancer Moonshot (1)
Clinical Trials (10)
COG (2)
Collaboration (11)
Comparative Oncology (1)
Data (15)
Delayed Diagnosis (2)
Digest (12)
Drug Development (12)
Drug Shortages (2)
Ethics (1)
Family Support (14)
FDA (1)
Funding Research (6)
Genomics (6)
Industry Perspective (5)
Member Access (12)
NCI (3)
Nutrition (1)
Patient-Reported Outcomes (1)
Prevention (5)
Psychosocial Support (4)
Rare and Ultra Rare Cancer (1)
Rare Cancers (1)
Regulations (3)
Research (38)
Research Advocacy (1)
Survivorship (26)
Venture Philanthropy (3)